1. [CASE 1 — QUESTION 1]
A 53-year-old man with type 2 diabetes mellitus (T2DM) for six years has a glycated hemoglobin (HbA1c) of 9.4 percent despite maximally tolerated metformin and good adherence. His body mass index (BMI) is 33, and he has no personal or family history of thyroid cancer. His clinician wants the single injectable agent most likely to drive his HbA1c toward target while also producing meaningful weight loss. Based on head-to-head trial evidence, which agent is best supported?
A) A dual GIP/GLP-1 receptor agonist (tirzepatide), which produced greater HbA1c reduction and greater weight loss than semaglutide in a direct head-to-head trial in metformin-treated T2DM
B) A selective glucagon-like peptide-1 receptor (GLP-1R) agonist, because it lowers HbA1c more than any dual agonist
C) A sulfonylurea, because it offers the most durable HbA1c reduction with weight loss
D) A sodium-glucose cotransporter-2 (SGLT-2) inhibitor, because it lowers HbA1c more than any injectable incretin agent
E) Basal insulin alone, because incretin agents do not meaningfully lower HbA1c on metformin
ANSWER: A
Rationale:
For a patient whose goals are maximal glycated hemoglobin (HbA1c) reduction and meaningful weight loss, the dual GIP/GLP-1 receptor agonist tirzepatide is best supported, because in a direct head-to-head trial in metformin-treated type 2 diabetes it produced greater HbA1c reduction and greater weight loss than semaglutide.
Option B: Option B is incorrect because the selective GLP-1R agonist did not exceed the dual agonist on HbA1c in the head-to-head comparison.
Option C: Option C is incorrect because sulfonylureas promote weight gain and tend to lose durability, and they did not outperform incretin agents on these goals.
Option D: Option D is incorrect because SGLT-2 inhibitors produce more modest HbA1c reductions than high-dose incretin agonists.
Option E: Option E is incorrect because incretin agents lower HbA1c effectively in metformin-treated patients, so basal insulin alone is not required.
2. [CASE 1 — QUESTION 2]
Continuing with the same patient. He asks how the recommended drug differs from the other injectable he has heard about. Which statement correctly describes the molecular basis of tirzepatide's "twincretin" designation?
A) It is a fixed physical combination of two separate selective peptides
B) It activates the glucagon-like peptide-1 receptor (GLP-1R) while blocking the glucose-dependent insulinotropic polypeptide receptor (GIPR)
C) It is a single peptide that acts as a balanced agonist at both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R)
D) It agonizes the glucagon receptor (GCGR) in addition to the GLP-1R
E) It is a GLP-1R agonist coformulated with metformin
ANSWER: C
Rationale:
Tirzepatide is a single peptide engineered to act as a balanced agonist at both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R), which is the basis for its "twincretin" designation.
Option A: Option A is incorrect because it is one peptide, not a physical combination of two separate selective peptides.
Option B: Option B is incorrect because tirzepatide agonizes rather than blocks the GIPR.
Option D: Option D is incorrect because adding glucagon receptor (GCGR) agonism describes the investigational triple agonist retatrutide, not tirzepatide.
Option E: Option E is incorrect because the twincretin term refers to dual incretin-receptor agonism in a single peptide, not coformulation with metformin.
3. [CASE 1 — QUESTION 3]
Continuing with the same patient. He is anxious about low blood sugars because a relative on a different diabetes drug has frequent hypoglycemia. Why does tirzepatide as monotherapy carry a low intrinsic hypoglycemia risk?
A) It stimulates insulin release independent of plasma glucose, producing a fixed output
B) Its insulinotropic effect is glucose-dependent, occurring chiefly when glucose is elevated and waning as glucose normalizes
C) It blocks insulin secretion entirely, preventing any glucose lowering
D) It raises plasma glucose through glucagon receptor agonism
E) It works only after hepatic conversion to an active metabolite that acts at night
ANSWER: B
Rationale:
Tirzepatide stimulates insulin secretion in a glucose-dependent manner, so the effect is greatest when plasma glucose is elevated and diminishes as glucose normalizes; this self-limiting action underlies the low intrinsic hypoglycemia risk of incretin-based monotherapy.
Option A: Option A is incorrect because the effect is glucose-dependent rather than a fixed, glucose-independent output.
Option C: Option C is incorrect because the drug promotes glucose-dependent insulin secretion rather than blocking it.
Option D: Option D is incorrect because tirzepatide has no glucagon receptor activity and lowers, rather than raises, glucose.
Option E: Option E is incorrect because tirzepatide acts directly at its receptors and does not depend on hepatic conversion to an active metabolite.
4. [CASE 1 — QUESTION 4]
Continuing with the same patient. He is started on tirzepatide. Which dosing and titration plan is correct?
A) Begin at 15 mg weekly and reduce as tolerated
B) Begin at 2.5 mg weekly and increase by 2.5 mg every week to a maximum of 50 mg
C) Give a single 15 mg dose without titration
D) Begin at 2.5 mg subcutaneously once weekly and increase by 2.5 mg no more often than every four weeks, to a maximum of 15 mg weekly, with the slow interval allowing gastrointestinal accommodation
E) Begin at 10 mg daily with no maximum specified
ANSWER: D
Rationale:
Tirzepatide is initiated at 2.5 mg subcutaneously once weekly and increased by 2.5 mg no more often than every four weeks toward the lowest effective dose, to a maximum of 15 mg weekly; the slow four-week interval allows gastrointestinal accommodation and limits nausea, vomiting, and diarrhea.
Option A: Option A is incorrect because therapy starts low and titrates upward rather than starting at the maximum.
Option B: Option B is incorrect because increments occur no more often than every four weeks and the maximum is 15 mg, not 50 mg.
Option C: Option C is incorrect because gradual titration is required rather than a single untitrated dose.
Option E: Option E is incorrect because tirzepatide is dosed once weekly, not daily, and has a specified 15 mg weekly maximum.
5. [CASE 2 — QUESTION 1]
A 39-year-old woman with obesity (body mass index 37) but without diabetes begins a glucagon-like peptide-1 receptor (GLP-1R) agonist for weight management. She reports markedly reduced appetite and early satiety. Integrating the central circuitry, which description best explains how GLP-1R agonism suppresses her appetite?
A) It enhances orexigenic neuropeptide Y (NPY)/agouti-related peptide (AgRP) neuron firing in the arcuate nucleus
B) It blocks vagal afferent satiety signaling at the nucleus tractus solitarius (NTS)
C) It acts only by raising adipose leptin synthesis, with no central neuronal effect
D) It suppresses anorexigenic pro-opiomelanocortin (POMC) neurons while stimulating hunger pathways
E) In the arcuate nucleus it suppresses orexigenic NPY/AgRP firing and enhances anorexigenic pro-opiomelanocortin (POMC) activity, while in the nucleus tractus solitarius (NTS) it amplifies vagal satiety signals from the gut
ANSWER: E
Rationale:
GLP-1R agonism shifts the arcuate balance toward reduced appetite by suppressing orexigenic neuropeptide Y (NPY)/agouti-related peptide (AgRP) neuron firing and enhancing anorexigenic pro-opiomelanocortin (POMC) activity, and in the nucleus tractus solitarius (NTS) it amplifies vagal satiety signals relayed from the gut, together producing appetite suppression and early satiety.
Option A: Option A is incorrect because GLP-1R agonism suppresses, rather than enhances, NPY/AgRP firing.
Option B: Option B is incorrect because it amplifies, rather than blocks, vagal satiety signaling at the NTS.
Option C: Option C is incorrect because GLP-1R agonism exerts direct central neuronal effects rather than acting solely through adipose leptin synthesis.
Option D: Option D is incorrect because GLP-1R agonism enhances POMC activity and suppresses hunger pathways rather than the reverse.
6. [CASE 2 — QUESTION 2]
Continuing with the same patient. She reads that a dual GIP/GLP-1 agonist might produce more weight loss than her current selective GLP-1R agonist even at comparable GLP-1R activation, and asks why. Which explanation is best supported?
A) The dual agonist works only by causing more nausea
B) Added central glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism contributes independently to appetite suppression beyond GLP-1R activation
C) The dual agonist blocks the GLP-1R, so less GLP-1R tone drives the extra weight loss
D) The dual agonist is dosed daily rather than weekly, giving more exposure
E) Glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism opposes weight loss, so the effect is from GLP-1R alone
ANSWER: B
Rationale:
At comparable GLP-1R activation, the dual agonist's additional central glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism contributes independently to appetite suppression, which is the most pharmacologically compelling explanation for its greater weight loss, supported by greater attenuation of food-cue reward responses.
Option A: Option A is incorrect because the advantage reflects genuine central and metabolic engagement, not merely more nausea.
Option C: Option C is incorrect because the dual agonist agonizes rather than blocks the GLP-1R.
Option D: Option D is incorrect because both agents are dosed once weekly in this comparison.
Option E: Option E is incorrect because central GIPR agonism augments rather than opposes the weight-loss effect.
7. [CASE 2 — QUESTION 3]
Continuing with the same patient. After six months she has lost 17 percent of her body weight but notices that her appetite seems to push back as the weight comes off. Which physiological mechanism best accounts for this counter-pressure?
A) As fat mass falls, declining leptin and insulin signaling increase orexigenic NPY/AgRP drive and reduce anorexigenic POMC signaling, defending the prior body weight set point, an effect the drug pharmacologically overrides rather than eliminates
B) Rising leptin from weight loss directly increases hunger
C) The drug permanently lowered her set point, so appetite counter-pressure cannot occur
D) Weight loss abolishes all hypothalamic appetite regulation
E) Falling glucagon levels increase appetite independently of leptin and insulin
ANSWER: A
Rationale:
As fat mass and body weight fall, leptin and insulin signaling decline, which increases orexigenic NPY/AgRP drive and decreases anorexigenic POMC signaling, producing a compensatory appetite increase that defends the prior set point; the drug pharmacologically overrides this resistance rather than eliminating it, so the counter-pressure is felt as weight comes off.
Option B: Option B is incorrect because leptin falls with weight loss, and it is the decline, not a rise, that drives hunger.
Option C: Option C is incorrect because the agent overrides rather than permanently resets the set point.
Option D: Option D is incorrect because hypothalamic appetite regulation remains active; it is precisely what generates the counter-pressure.
Option E: Option E is incorrect because the rebound is governed by falling leptin and insulin acting on hypothalamic circuits, not by a glucagon-driven mechanism independent of them.
8. [CASE 2 — QUESTION 4]
Continuing with the same patient. She is considering stopping the drug now that she has reached her goal weight and asks what to expect. Which counseling is best supported?
A) Her weight will remain stable because the drug reset her set point
B) Any regain would reflect only insufficient willpower, not physiology
C) Because the drug overrides rather than resets the defended set point, stopping it is expected to unmask orexigenic rebound and cause substantial regain over the following months, so therapy is best framed as chronic, with behavioral support and a plan for re-initiation if needed
D) Stopping the drug will permanently suppress her appetite
E) Re-initiating the drug later would be ineffective due to permanent tolerance
ANSWER: C
Rationale:
Because incretin agonists override rather than reset the defended weight set point, discontinuation unmasks the orexigenic rebound and substantial weight regain is expected over the following months; the supported counseling frames pharmacotherapy as chronic and arranges behavioral support and a plan for re-initiation if needed.
Option A: Option A is incorrect because the set point is overridden, not reset, so weight does not remain stable after stopping.
Option B: Option B is incorrect because regain is a predicted physiological consequence rather than a failure of willpower.
Option D: Option D is incorrect because stopping removes appetite suppression rather than making it permanent.
Option E: Option E is incorrect because re-initiation can restore the effect; tolerance is not permanent.
9. [CASE 3 — QUESTION 1]
A 60-year-old woman with type 2 diabetes mellitus (T2DM) is on basal insulin, metformin, and lifestyle therapy, with a glycated hemoglobin (HbA1c) of 8.6 percent and fasting glucose of 130 to 150 mg/dL. Her clinician plans to add tirzepatide. What initial adjustment most appropriately addresses hypoglycemia risk at the time tirzepatide is started?
A) Increase the basal insulin dose by 20 percent
B) Make no change to insulin and recheck HbA1c in three months
C) Stop the basal insulin entirely with the first tirzepatide dose
D) Reduce the basal insulin dose by approximately 20 percent at tirzepatide initiation, with further titration guided by fasting glucose monitoring
E) Add a sulfonylurea to ease the transition
ANSWER: D
Rationale:
When tirzepatide is added to basal insulin, reducing the basal insulin dose by approximately 20 percent at initiation, with further titration guided by fasting glucose monitoring, appropriately mitigates the added hypoglycemia risk from the combined glucose-lowering effect.
Option A: Option A is incorrect because increasing basal insulin compounds the effect and raises hypoglycemia risk.
Option B: Option B is incorrect because leaving insulin unchanged ignores the additive effect.
Option C: Option C is incorrect because abruptly stopping basal insulin in an insulin-requiring patient risks hyperglycemia and is not the recommended initiation step.
Option E: Option E is incorrect because adding a sulfonylurea would increase, not reduce, hypoglycemia risk.
10. [CASE 3 — QUESTION 2]
Continuing with the same patient. She asks whether she still needs to check her glucose now that she is on an agent with low intrinsic hypoglycemia risk. Which explanation is correct?
A) Glucose monitoring can be stopped because tirzepatide eliminates hypoglycemia risk entirely
B) Monitoring is unnecessary because basal insulin no longer contributes to glucose lowering once tirzepatide is added
C) Monitoring remains essential because, although tirzepatide's insulin effect is glucose-dependent and self-limiting, basal insulin lowers glucose in a glucose-independent manner, so the combination still carries hypoglycemia risk and guides dose titration
D) Monitoring is needed only if she develops symptoms of hyperglycemia
E) Monitoring is needed because tirzepatide raises blood glucose
ANSWER: C
Rationale:
Monitoring remains essential because tirzepatide's insulinotropic effect is glucose-dependent and self-limiting, but basal insulin lowers glucose in a glucose-independent manner, so the combination still carries hypoglycemia risk and fasting glucose values guide insulin titration.
Option A: Option A is incorrect because tirzepatide reduces but does not eliminate hypoglycemia risk, especially with concurrent insulin.
Option B: Option B is incorrect because basal insulin continues to lower glucose after tirzepatide is added.
Option D: Option D is incorrect because monitoring is needed to detect and prevent hypoglycemia and to guide titration, not only for hyperglycemia symptoms.
Option E: Option E is incorrect because tirzepatide lowers, rather than raises, blood glucose.
11. [CASE 3 — QUESTION 3]
Continuing with the same patient. At a later visit she reports a friend suggested also adding a separate glucagon-like peptide-1 receptor (GLP-1R) agonist and pramlintide for faster results. What is the most appropriate guidance?
A) Add both agents, since stacking incretin and amylin agents multiplies benefit
B) Do not add another GLP-1R agonist or pramlintide to tirzepatide, because these overlapping mechanisms provide no additive benefit and increase adverse-effect risk
C) Add the GLP-1R agonist but not pramlintide, since two GLP-1R agonists are safe together
D) Add pramlintide and double the basal insulin to compensate
E) Replace tirzepatide with all three agents used together
ANSWER: B
Rationale:
Tirzepatide should not be combined with another glucagon-like peptide-1 receptor (GLP-1R) agonist or with pramlintide, because the overlapping incretin and amylin-related mechanisms provide no additive benefit and increase adverse-effect risk.
Option A: Option A is incorrect because stacking these agents does not multiply benefit and raises risk.
Option C: Option C is incorrect because adding a second GLP-1R agonist is a redundant overlap, not a safe combination.
Option D: Option D is incorrect because pramlintide overlaps mechanistically and doubling basal insulin would sharply increase hypoglycemia risk.
Option E: Option E is incorrect because using all three overlapping agents together compounds risk without added benefit.
12. [CASE 3 — QUESTION 4]
Continuing with the same patient. Her clinician explains that, rather than intensifying with mealtime (prandial) insulin, adding a dual incretin agonist to her basal insulin is preferred. Based on trial evidence in patients inadequately controlled on basal insulin, what outcome supports this preference?
A) Adding the dual GIP/GLP-1 agonist to basal insulin produced greater HbA1c reduction with lower rates of hypoglycemia and greater weight loss than adding thrice-daily prandial insulin
B) Adding prandial insulin produced greater weight loss than the dual agonist
C) The dual agonist worsened glycemic control compared with prandial insulin
D) Adding prandial insulin produced less hypoglycemia than the dual agonist
E) Neither strategy changed HbA1c in basal-insulin-treated patients
ANSWER: A
Rationale:
In patients inadequately controlled on basal insulin, adding the dual GIP/GLP-1 agonist produced greater glycated hemoglobin (HbA1c) reduction with lower rates of hypoglycemia and greater weight loss than intensifying with thrice-daily prandial insulin, supporting the incretin-based strategy.
Option B: Option B is incorrect because prandial insulin promotes weight gain rather than greater weight loss.
Option C: Option C is incorrect because the dual agonist improved, not worsened, glycemic control relative to prandial insulin.
Option D: Option D is incorrect because prandial insulin was associated with more, not less, hypoglycemia than the dual agonist.
Option E: Option E is incorrect because both strategies lower HbA1c; the comparison concerns the magnitude of benefit and the adverse-effect profile.
13. [CASE 4 — QUESTION 1]
A 58-year-old man with type 2 diabetes mellitus (T2DM), body mass index 35, and biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) with stage F2 fibrosis needs pharmacotherapy that benefits both his diabetes and his liver disease. He has mild peripheral edema. Which agent is the better choice, and why?
A) Pioglitazone, because its associated weight gain benefits MASH
B) A sulfonylurea, because it is the preferred agent for MASH
C) A dual GIP/GLP-1 agonist (tirzepatide), because it provides glycemic control, substantial weight loss, and direct hepatic benefit, whereas pioglitazone promotes weight gain, fluid retention that could worsen his edema, and bone loss
D) No pharmacotherapy, because no agent benefits MASH
E) Pioglitazone, because it has no effect on fluid balance
ANSWER: C
Rationale:
The dual GIP/GLP-1 agonist is the better choice because it offers glycemic control, substantial weight loss, and direct hepatic benefit in MASH, with weight loss itself ameliorating hepatic steatosis and inflammation; pioglitazone, although histologically active, promotes weight gain, fluid retention that could worsen this patient's edema, and bone loss.
Option A: Option A is incorrect because weight gain is not beneficial in an obese patient with MASH.
Option B: Option B is incorrect because sulfonylureas are not preferred for MASH and lack histological benefit.
Option D: Option D is incorrect because effective pharmacotherapy with hepatic benefit exists.
Option E: Option E is incorrect because pioglitazone does cause fluid retention.
14. [CASE 4 — QUESTION 2]
Continuing with the same patient. He asks how a drug given for diabetes and weight could help his liver. Integrating the pathophysiology, which explanation is best supported?
A) MASH is unrelated to insulin resistance or adiposity, so weight loss is irrelevant
B) The drug helps the liver only by directly inhibiting hepatic fibrogenesis, independent of weight or metabolism
C) The drug helps only by lowering blood glucose, with no contribution from weight loss
D) MASH improves because the drug increases hepatic fat storage
E) Because MASH is driven by obesity, type 2 diabetes, and insulin resistance, the substantial weight loss and improved insulin sensitivity from the agent reduce hepatic steatosis and inflammation, addressing the metabolic drivers of the disease
ANSWER: E
Rationale:
Metabolic dysfunction-associated steatohepatitis (MASH) is driven by obesity, type 2 diabetes, and insulin resistance, so the substantial weight loss and improved insulin sensitivity produced by the dual incretin agonist reduce hepatic steatosis and inflammation, addressing the underlying metabolic drivers.
Option A: Option A is incorrect because MASH is strongly linked to insulin resistance and adiposity.
Option B: Option B is incorrect because the benefit is substantially metabolic and weight-mediated rather than a direct antifibrotic action independent of metabolism.
Option C: Option C is incorrect because weight loss, not glucose lowering alone, is central to the hepatic benefit.
Option D: Option D is incorrect because the agent reduces, rather than increases, hepatic fat.
15. [CASE 4 — QUESTION 3]
Continuing with the same patient. For comparison, his clinician describes pioglitazone, the agent previously most studied for MASH histology. Which statement about pioglitazone is correct?
A) It is a glucagon-like peptide-1 receptor (GLP-1R) agonist that produces weight loss
B) It has no demonstrated histological benefit in MASH
C) It is an incretin agonist sharing tirzepatide's mechanism
D) It is a peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist with demonstrated histological efficacy in MASH but promotes weight gain, fluid retention, and bone loss
E) It is contraindicated in all patients with type 2 diabetes
ANSWER: D
Rationale:
Pioglitazone is a peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist with demonstrated histological efficacy in MASH, but it promotes weight gain, fluid retention, and bone loss, which limit its use relative to incretin-based therapy in obese patients.
Option A: Option A is incorrect because pioglitazone is a PPAR-gamma agonist, not a GLP-1R agonist, and it causes weight gain rather than weight loss.
Option B: Option B is incorrect because pioglitazone does have demonstrated histological benefit in MASH.
Option C: Option C is incorrect because pioglitazone does not share the incretin mechanism of tirzepatide.
Option E: Option E is incorrect because pioglitazone is not contraindicated in all type 2 diabetes; its use is limited by specific adverse effects rather than a blanket contraindication.
16. [CASE 4 — QUESTION 4]
Continuing with the same patient. He wants to know whether the dual agonist actually outperforms pioglitazone on liver histology. Based on the trial evidence for tirzepatide in biopsy-confirmed MASH, which statement is best supported?
A) Tirzepatide produced lower MASH resolution rates than pioglitazone
B) Tirzepatide produced MASH resolution rates that substantially exceeded those historically seen with pioglitazone, while also producing weight loss rather than weight gain
C) Tirzepatide produced no MASH resolution beyond placebo
D) Pioglitazone resolves MASH in nearly all treated patients, far exceeding tirzepatide
E) Neither agent affects MASH histology
ANSWER: B
Rationale:
In its trial in biopsy-confirmed MASH, tirzepatide produced MASH resolution rates that substantially exceeded those historically seen with pioglitazone, and it did so while producing weight loss rather than the weight gain associated with pioglitazone, supporting its selection for a patient with T2DM, obesity, and MASH.
Option A: Option A is incorrect because tirzepatide produced higher, not lower, resolution rates than pioglitazone.
Option C: Option C is incorrect because tirzepatide produced markedly greater MASH resolution than placebo.
Option D: Option D is incorrect because pioglitazone resolves MASH in roughly a third to 40 percent of patients, not nearly all, and does not exceed tirzepatide.
Option E: Option E is incorrect because both agents affect MASH histology; the comparison concerns the magnitude of benefit and the weight effect.
17. [CASE 5 — QUESTION 1]
A 70-year-old woman with body mass index 38 has heart failure with preserved ejection fraction (HFpEF), with exertional dyspnea and reduced exercise capacity. She has type 2 diabetes mellitus (T2DM). Her care team is evaluating how her obesity contributes to her heart failure. Which description of obesity-related HFpEF pathophysiology is correct?
A) It involves epicardial fat infiltration, pericardial constraint, neurohormonal activation, and inflammation with impaired myocardial relaxation, so weight reduction can lessen these obesity-driven contributors
B) It is driven primarily by reduced systolic contractility from obesity
C) Obesity plays no mechanistic role in HFpEF
D) It is caused solely by coronary artery occlusion
E) It results from a primary valvular abnormality unrelated to adiposity
ANSWER: A
Rationale:
Obesity-related HFpEF involves epicardial fat infiltration, pericardial constraint, neurohormonal activation, and inflammation with impaired myocardial relaxation, so weight reduction can lessen these obesity-driven contributors and improve symptoms.
Option B: Option B is incorrect because HFpEF is defined by preserved ejection fraction with impaired relaxation rather than reduced systolic contractility.
Option C: Option C is incorrect because obesity is a central mechanistic driver of this phenotype.
Option D: Option D is incorrect because the phenotype is not caused solely by coronary occlusion.
Option E: Option E is incorrect because it does not result from a primary valvular abnormality unrelated to adiposity.
18. [CASE 5 — QUESTION 2]
Continuing with the same patient. Her team weighs a dual GIP/GLP-1 agonist against a selective glucagon-like peptide-1 receptor (GLP-1R) agonist for her obesity-related HFpEF. Based on the dedicated HFpEF trials of each, how do their demonstrated outcomes differ?
A) Neither agent showed any benefit in HFpEF
B) The selective GLP-1R agonist reduced the combined cardiovascular event endpoint while the dual agonist worsened heart failure
C) Both agents reduced the combined cardiovascular death or worsening heart failure event endpoint equally
D) The dual agonist improved only symptoms while the selective GLP-1R agonist reduced events
E) The dual agonist reduced the composite of cardiovascular death or worsening heart failure events, whereas the selective GLP-1R agonist improved symptom and functional measures without a significant reduction in that combined event endpoint
ANSWER: E
Rationale:
In their dedicated HFpEF trials, the dual GIP/GLP-1 agonist reduced the composite of cardiovascular death or worsening heart failure events, whereas the selective GLP-1R agonist improved symptom burden and functional measures without a significant reduction in that combined event endpoint.
Option A: Option A is incorrect because both agents demonstrated benefit, differing in whether the combined event endpoint was significantly reduced.
Option B: Option B is incorrect because it reverses the findings and wrongly states the dual agonist worsened heart failure.
Option C: Option C is incorrect because the two agents did not reduce the combined event endpoint equally; only the dual agonist significantly reduced that composite.
Option D: Option D is incorrect because it reverses which agent reduced events versus improved symptoms.
19. [CASE 5 — QUESTION 3]
Continuing with the same patient. Her team wants to ensure her HFpEF regimen reflects the strongest available outcome evidence. Which drug class should anchor her heart failure therapy, independent of her obesity status?
A) Selective glucagon-like peptide-1 receptor (GLP-1R) agonists, because they have the strongest HFpEF outcome evidence
B) Sulfonylureas, because they improve HFpEF outcomes
C) Thiazolidinediones, because they are preferred in HFpEF
D) Sodium-glucose cotransporter-2 (SGLT-2) inhibitors, because they retain the strongest HFpEF outcome evidence regardless of obesity status
E) Dual GIP/GLP-1 agonists, because they replace all other HFpEF therapy
ANSWER: D
Rationale:
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors retain the strongest HFpEF outcome evidence regardless of obesity status and should anchor her heart failure therapy, with incretin-based weight loss serving a complementary role.
Option A: Option A is incorrect because selective GLP-1R agonists improved symptoms but did not establish the strongest HFpEF outcome evidence.
Option B: Option B is incorrect because sulfonylureas do not improve HFpEF outcomes.
Option C: Option C is incorrect because thiazolidinediones promote fluid retention and are not preferred in heart failure.
Option E: Option E is incorrect because dual GIP/GLP-1 agonists complement rather than replace established HFpEF therapy.
20. [CASE 5 — QUESTION 4]
Continuing with the same patient, who also has established atherosclerotic cardiovascular disease (ASCVD). Her team considers the cardiovascular safety of the dual GIP/GLP-1 agonist, noting its outcomes trial used an active comparator with proven cardiovascular benefit. What does the non-inferiority result indicate?
A) The dual agonist increases major adverse cardiovascular events relative to placebo
B) The result is uninterpretable because the comparator was inert
C) Because the comparator was a glucagon-like peptide-1 receptor (GLP-1R) agonist with established cardiovascular benefit, non-inferiority indicates the dual agonist preserves the cardioprotection of the incretin class rather than merely beating placebo
D) The active-comparator design prevented any mortality assessment
E) Non-inferiority means the dual agonist has no metabolic advantage and should be avoided
ANSWER: C
Rationale:
Because the cardiovascular outcomes trial compared the dual agonist against a glucagon-like peptide-1 receptor (GLP-1R) agonist with established cardiovascular benefit, demonstrating non-inferiority for the major adverse cardiovascular event composite indicates the dual agonist preserves the cardioprotection of the incretin class rather than merely beating placebo.
Option A: Option A is incorrect because the result indicates preserved protection, not increased cardiovascular events.
Option B: Option B is incorrect because the comparator was an active cardioprotective agent, which is what makes the design informative.
Option D: Option D is incorrect because the design did not preclude mortality assessment; a reduction in all-cause mortality was reported.
Option E: Option E is incorrect because preserved cardiovascular protection coexists with the agent's metabolic advantages, so the result does not argue against its use.
21. [CASE 6 — QUESTION 1]
A 46-year-old man with type 2 diabetes mellitus (T2DM) would benefit from incretin therapy but has a severe needle phobia and finds the strict fasting-and-wait instructions for peptide oral therapy impractical. Among emerging agents, which approach best addresses his barriers, and why?
A) An injectable dual agonist given by a caregiver, since oral incretin therapy is impossible
B) An oral non-peptide small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist, because its conventional small-molecule absorption avoids injection and does not require the permeation enhancer or strict fasting administration that peptide oral semaglutide needs
C) Peptide oral semaglutide, because it can be taken with food at any time
D) A compounded injectable, because compounding converts it to an oral product
E) No incretin therapy is possible without injection
ANSWER: B
Rationale:
An oral non-peptide small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist best addresses his barriers because its oral bioavailability arises from conventional small-molecule absorption, avoiding injection and removing the need for the permeation enhancer and strict fasting administration that peptide oral semaglutide requires.
Option A: Option A is incorrect because effective oral incretin therapy is feasible, so caregiver-administered injection is not the only option.
Option C: Option C is incorrect because peptide oral semaglutide requires a permeation enhancer and strict fasting administration, not dosing with food at any time.
Option D: Option D is incorrect because compounding does not convert an injectable into an oral product.
Option E: Option E is incorrect because emerging oral agents make non-injection incretin therapy possible.
22. [CASE 6 — QUESTION 2]
Continuing with the same patient. He has read about an investigational triple agonist (retatrutide) and asks how adding glucagon receptor (GCGR) activity could aid weight loss without worsening his diabetes. Which explanation is best supported?
A) GCGR agonism raises energy expenditure through hepatic fatty acid oxidation and brown adipose thermogenesis, while the dominant GLP-1R-mediated glucose-dependent insulin secretion and suppression of endogenous glucagon offset the hyperglycemic tendency of glucagon-receptor activation
B) GCGR agonism lowers energy expenditure, so glycemia is preserved by reduced metabolic demand
C) The agent omits GLP-1R activity and relies on GCGR alone to avoid hyperglycemia
D) GCGR agonism aids weight loss only through renal calorie loss with no glycemic interaction
E) Adding GCGR agonism necessarily causes uncontrolled hyperglycemia, so the strategy cannot work
ANSWER: A
Rationale:
A triple agonist raises energy expenditure through glucagon receptor (GCGR)-driven hepatic fatty acid oxidation and brown adipose tissue thermogenesis, while the dominant GLP-1R-mediated, glucose-dependent insulin secretion together with GLP-1R-driven suppression of endogenous glucagon offsets the hyperglycemic tendency of glucagon-receptor activation, allowing added weight loss without worsening glycemia.
Option B: Option B is incorrect because GCGR agonism raises rather than lowers energy expenditure.
Option C: Option C is incorrect because the agent retains GLP-1R activity, which is what offsets the glucagon-driven glycemic effect.
Option D: Option D is incorrect because the energy-expenditure effect is mediated by hepatic and brown-fat metabolism, not renal calorie loss, and it does interact with glycemia.
Option E: Option E is incorrect because the counterbalancing GLP-1R effects prevent uncontrolled hyperglycemia.
23. [CASE 6 — QUESTION 3]
Continuing with the same patient. He also asks about an amylin-based combination (cagrilintide plus semaglutide, "CagriSema"). Which statement about cagrilintide is correct?
A) It is a glucagon-like peptide-1 receptor (GLP-1R) agonist identical to semaglutide
B) It is a peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist
C) It is a sodium-glucose cotransporter-2 (SGLT-2) inhibitor
D) It is a glucose-dependent insulinotropic polypeptide receptor (GIPR) agonist
E) It is a long-acting amylin analog dosed once weekly that, combined with semaglutide, produced substantially greater weight loss than either agent alone, in contrast to the native amylin analog pramlintide, which requires thrice-daily injection
ANSWER: E
Rationale:
Cagrilintide is a long-acting amylin analog engineered for once-weekly dosing; combined with semaglutide as CagriSema it produced substantially greater weight loss than either agent alone, in contrast to the native amylin analog pramlintide, which requires thrice-daily injection and produces only modest weight loss.
Option A: Option A is incorrect because cagrilintide is an amylin analog, not a GLP-1R agonist identical to semaglutide.
Option B: Option B is incorrect because it is not a PPAR-gamma agonist.
Option C: Option C is incorrect because it is not an SGLT-2 inhibitor.
Option D: Option D is incorrect because it activates amylin receptors rather than acting as a GIPR agonist.
24. [CASE 6 — QUESTION 4]
Continuing with the same patient. During the discussion, he mentions that his father and sister both had medullary thyroid carcinoma (MTC), and the family carries multiple endocrine neoplasia type 2 (MEN2). How should this affect the plan for incretin-based therapy?
A) It is irrelevant, since emerging oral agents are exempt from the class contraindication
B) Proceed with an injectable dual agonist but add monthly thyroid ultrasound
C) Do not prescribe incretin-based therapy with this class contraindication; a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2) contraindicates these agents, and an alternative drug class should be selected
D) Prescribe a triple agonist instead, which carries no thyroid-related concern
E) Prescribe any incretin agent as long as he agrees to prophylactic thyroidectomy first
ANSWER: C
Rationale:
A personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2) contraindicates incretin-based agents carrying this class warning, so therapy should not be prescribed and an alternative drug class should be selected.
Option A: Option A is incorrect because the class contraindication is not waived for emerging incretin-based oral agents that carry the same warning.
Option B: Option B is incorrect because surveillance does not override an absolute class contraindication.
Option D: Option D is incorrect because triple agonists share the incretin-based class concern and are investigational, so they are not a contraindication-sparing substitute.
Option E: Option E is incorrect because prophylactic thyroidectomy is not an accepted means of enabling use of a contraindicated agent.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.